Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Von Willebrand Disease, Type 3
Concomitant VWD and Hemophilia

Interventions

DRUG: Emicizumab

Sponsor

Bleeding and Clotting Disorders Institute Peoria, Illinois

Collaborators

[object Object]